The data of the paper referenced in the preparation of the protocols in this task were manipulated and the paper was withdrawn.

To study the effect of olmesartan on walking distance and quality of life in peripheral artery disease patients with hypertension treated For intermittent claudication.

Inclusion Criteria:

• Aged between 20 and 85 years at visit 1
• Patients with ankle-brachial index (ABI) of less than 0.9 in one or both legs with history of intermittent claudication stable for the previous 6 months
• Patients whose statins, anti hypertensive medications and antiplatelet medications are stable for the past 6 months. Statins and cilostazol are allowed but needs to be stable for the past 6 months (diabetic medications may be changed)
• Patients whose blood pressure is more than 140/90 mmHg with/without anti-hypertension treatment

Exclusion Criteria:

• Blood pressure of more than 180/110 mmHg
• Patients taking ARBs or ACE inhibitors treatment for at least 6 months before
• Patients taking aldosterone receptor antagonists at least 6 months before
• Patients with serum creatinine of more than 3 mg/dL
• serum potassium (K+) > 5.5mg/dl
• History of bilateral renal artery stenosis
• History of acute coronary syndrome or heart failure hospitalization within 6 months
• Peripheral arterial revascularization planned within 1 month
• Critical limb ischemia
• Patients with impaired cognition (e.g. dementia)
• pregnancy or women at age of childbearing potential